Literature DB >> 22266513

A genetic epidemiologic study of candidate genes involved in the optic nerve head morphology.

Andrea C Gasten1, Wishal D Ramdas, Linda Broer, Leonieke M E van Koolwijk, M Kamran Ikram, Paulus T V M de Jong, Yurii S Aulchenko, Roger C Wolfs, Albert Hofman, Fernando Rivadeneira, Andre G Uitterlinden, Ben A Oostra, Hans G Lemij, Caroline C W Klaver, Nomdo M Jansonius, Johannes R Vingerling, Cornelia M van Duijn.   

Abstract

PURPOSE: The size of the optic nerve head, referred to as disc area (DA), and the vertical cup-disc ratio (VCDR), are clinically relevant parameters for glaucomatous optic neuropathy. Although these measures have a high heritability, little is known about the underlying genes. Previously, the genes SALL1 and SIX1 were found to be genome-wide significantly associated with DA and VCDR. The purpose of the present study was to investigate whether genes encoding protein known to interact with protein encoded by SALL1 and SIX1 are also associated with either DA or VCDR.
METHODS: A total of 38 candidate genes were chosen covering all known proteins interacting with SALL1 and SIX1. These were initially studied in the Rotterdam Study (RS)-I, including 5312 Caucasian subjects characterized for DA and VCDR. Positive findings were further investigated in two independent cohorts (RS-II and RS-III) and finally replicated in a fourth population (ERF). Bonferroni correction was applied to the meta-analyses.
RESULTS: Three loci were found to be associated with DA. The only locus significant after correcting for multiple testing is located on chromosome 11p13. Three single nucleotide polymorphisms (SNPs) in ELP4, a gene which neighbors and plays a crucial role in the expression of PAX6, show association in meta-analysis of the four cohorts yielding P values of respectively 4.79 × 10(-6), 3.92 × 10(-6), and 4.88 × 10(-6) which is below the threshold dictated by the most conservative Bonferroni correction (P = 5.2 × 10(-6)).
CONCLUSIONS: This study suggests that the ELP4-PAX6 region plays a role in the DA. Further research to confirm this finding is needed.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22266513     DOI: 10.1167/iovs.11-7384

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  4 in total

Review 1.  Genes, pathways, and animal models in primary open-angle glaucoma.

Authors:  A I Iglesias; H Springelkamp; W D Ramdas; C C W Klaver; R Willemsen; C M van Duijn
Journal:  Eye (Lond)       Date:  2015-08-28       Impact factor: 3.775

Review 2.  Major review: Molecular genetics of primary open-angle glaucoma.

Authors:  Yutao Liu; R Rand Allingham
Journal:  Exp Eye Res       Date:  2017-05-10       Impact factor: 3.467

3.  A novel 11p13 microdeletion encompassing PAX6 in a Chinese Han family with aniridia, ptosis and mental retardation.

Authors:  Ping Hu; Lulu Meng; Dingyuan Ma; Fengchang Qiao; Yan Wang; Jing Zhou; Long Yi; Zhengfeng Xu
Journal:  Mol Cytogenet       Date:  2015-01-22       Impact factor: 2.009

4.  Common variants at 9p21 and 8q22 are associated with increased susceptibility to optic nerve degeneration in glaucoma.

Authors:  Janey L Wiggs; Brian L Yaspan; Michael A Hauser; Jae H Kang; R Rand Allingham; Lana M Olson; Wael Abdrabou; Bao J Fan; Dan Y Wang; Wendy Brodeur; Donald L Budenz; Joseph Caprioli; Andrew Crenshaw; Kristy Crooks; Elizabeth Delbono; Kimberly F Doheny; David S Friedman; Douglas Gaasterland; Terry Gaasterland; Cathy Laurie; Richard K Lee; Paul R Lichter; Stephanie Loomis; Yutao Liu; Felipe A Medeiros; Cathy McCarty; Daniel Mirel; Sayoko E Moroi; David C Musch; Anthony Realini; Frank W Rozsa; Joel S Schuman; Kathleen Scott; Kuldev Singh; Joshua D Stein; Edward H Trager; Paul Vanveldhuisen; Douglas Vollrath; Gadi Wollstein; Sachiko Yoneyama; Kang Zhang; Robert N Weinreb; Jason Ernst; Manolis Kellis; Tomohiro Masuda; Don Zack; Julia E Richards; Margaret Pericak-Vance; Louis R Pasquale; Jonathan L Haines
Journal:  PLoS Genet       Date:  2012-04-26       Impact factor: 5.917

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.